Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications

被引:0
|
作者
Jan-Peter van Wieringen
Jan Booij
Vladimir Shalgunov
Philip Elsinga
Martin C. Michel
机构
[1] University of Amsterdam,Department of Nuclear Medicine, Academic Medical Center
[2] University of Groningen,Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen
[3] Johannes Gutenberg University,Department of Pharmacology
[4] Johannes Gutenberg Universität,Institut für Pharmakologie
关键词
Agonist high-affinity state; Dopamine receptor; Psychosis; [; H]-spiperone;
D O I
暂无
中图分类号
学科分类号
摘要
Dopamine D2 receptors, similar to other G-protein-coupled receptors, exist in a high- and low-affinity state for agonists. Based upon a review of the methods for detecting D2 receptor agonist high-affinity states, we discuss alterations of such states in animal models of disease and the implications of such alterations for their labelling with positron emission tomography (PET) and single-photon emission computed tomography (SPECT) tracers. The classic approach of detecting agonist high-affinity states compares agonist competition for antagonist radioligands, in most cases using [3H]-spiperone as the radioligand; alternative approaches and radioligands have been proposed, but their claimed advantages have not been substantiated by other investigators. In view of the advantages and disadvantages of various techniques, we critically have reviewed reported findings on the detection of D2 receptor agonist high-affinity states in a variety of animal models. These data are compared to the less numerous findings from human in vivo studies based on PET and SPECT tracers; they are interpreted in light of the finding that D2 receptor agonist high-affinity states under control conditions may differ between rodent and human brain. The potential advantages of agonist ligands in studies of pathophysiology and as diagnostics are being discussed.
引用
收藏
页码:135 / 154
页数:19
相关论文
共 50 条
  • [31] Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia
    Kubota, Manabu
    Nagashima, Tomohisa
    Takano, Harumasa
    Kodaka, Fumitoshi
    Fujiwara, Hironobu
    Takahata, Keisuke
    Moriguchi, Sho
    Kimura, Yasuyuki
    Higuchi, Makoto
    Okubo, Yoshiro
    Takahashi, Hidehiko
    Ito, Hiroshi
    Suhara, Tetsuya
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2017, 20 (11): : 928 - 935
  • [32] Electrophysiological evidence for high- and low-affinity CCK-A receptors in gastric vagal afferents
    Wei, JY
    Wang, YH
    Adelson, D
    Zhou, SY
    Lu, YX
    Chung, OY
    GASTROENTEROLOGY, 2004, 126 (04) : A116 - A116
  • [33] DU 127090:: A novel partial dopamine agonist with antipsychotic activity high potency but low efficacy at dopamine D2 receptors in vitro
    Hesselink, MB
    van Vliet, BJ
    Ronken, E
    Tulp, M
    Long, SK
    Feenstra, RW
    Kruse, CG
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 108 - 108
  • [34] STIMULATION OF HIGH-AFFINITY ADENOSINE-A2 RECEPTORS DECREASES THE AFFINITY OF DOPAMINE D2 RECEPTORS IN RAT STRIATAL MEMBRANES
    FERRE, S
    VONEULER, G
    JOHANSSON, B
    FREDHOLM, BB
    FUXE, K
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (16) : 7238 - 7241
  • [35] (-)S amisulpride binds with high affinity to cloned dopamine D3 and D2 receptors
    Castelli, MP
    Mocci, I
    Sanna, AM
    Gessa, GL
    Pani, L
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 432 (2-3) : 143 - 147
  • [36] An agonist at glutamate and dopamine D2 receptors, LY404039
    Seeman, Philip
    NEUROPHARMACOLOGY, 2013, 66 : 87 - 88
  • [37] Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor
    Kapur, S
    Seeman, P
    BIOLOGICAL PSYCHIATRY, 2001, 49 (11) : 954 - 955
  • [38] HIGH-AFFINITY AND LOW-AFFINITY STATES OF STRIATAL-D2 RECEPTORS ARE NOT AFFECTED BY 6-HYDROXYDOPAMINE OR CHRONIC HALOPERIDOL TREATMENT
    MACKENZIE, RG
    ZIGMOND, MJ
    JOURNAL OF NEUROCHEMISTRY, 1984, 43 (05) : 1310 - 1318
  • [39] Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors
    Wood, Martyn
    Dubois, Vanessa
    Scheller, Dieter
    Gillard, Michel
    BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (04) : 1124 - 1135
  • [40] Aripiprazole: Examining the Clinical Implications of D2 Affinity
    Anam, Adiba
    Lynch, Sean
    Mosharraf, Nafiz
    Soukas, Chloe
    Gekhman, Dmitriy
    CNS SPECTRUMS, 2023, 28 (02)